Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
ConditionAtypical Hemolytic-Uremic Syndrome
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAlexion Pharmaceuticals, Inc.
About this trial
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
Eligibility criteria
Qualifiers
Male or female patients of any age, including minors, who have been diagnosed with aHUS
Patients with or without an identified complement pathogenic variant or anti-complement factor antibody
Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent [if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].
ADAMTS13 > 5%, if performed.
Disqualifiers
Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli (STEC).
Unable to give written informed consent. Patient or patient's parent/legal guardian unable to give written informed consent. Patient (if minor) unable to give written informed assent (if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees [IRB/IEC]).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Alexion Pharmaceuticals, Inc.
Lead sponsor
Syneos Health
Collaborator
Source ClinicalTrials.gov